Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 20, 2020

VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours

VelosBio announced that the first patient has been dosed in a Phase 2 trial of VLS-101 in patients with solid tumors. VLS-101, the company’s lead product candidate, is an antibody-drug conjugate (ADC) that targets ROR1.

VelosBio announces first patient dosed in phase 2 trial of VLS-101 in solid tumours